Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II oral vinorelbine + capecitabine in previously anthracycline- and taxane-treated metastatic breast cancer
2004-000665-35Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Apr 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and capecitabine in breast cancer, sponsored by Pierre Fabre Laboratories. Primary endpoint: Response rate. Started Apr 2012; status: completed.
02
Drugs
vinorelbinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-000665-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000665-35.